Regen BioPharma Inc (RGBPP)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 09-30. Amounts in USD.

Revenue Quarterly

0 70K 140K 210K Q2 '13: 0 Q3 '13: 0 Q1 '14: 0 Q2 '14: 0 Q3 '14: 0 Q4 '14: 0 Q1 '15: 0 Q2 '15: 0 Q3 '15: 0 Q4 '15: 192K Q1 '16: 0 Q2 '16: 0 Q3 '16: 0 Q4 '16: 100K Q1 '17: 0 Q2 '17: 0 Q3 '17: 110K Q4 '17: 0 Q1 '18: 0 Q2 '18: 0 Q3 '18: 100K Q4 '18: 0 Q1 '19: 27.4K Q2 '19: 27.4K Q3 '19: 27.4K Q4 '19: 27.7K Q1 '20: 27.4K Q2 '20: 27.4K Q3 '20: 27.4K Q4 '20: 27.7K Q1 '21: 27.4K Q2 '21: 27.4K Q3 '21: 29.2K Q4 '21: 32K Q1 '22: 31.6K Q2 '22: 30.9K Q3 '22: 31.3K Q4 '22: 31.6K Q1 '23: 31.6K Q2 '23: 31.6K Q3 '23: 31.6K Q4 '23: 141.6K Q1 '24: 59.1K Q2 '24: 59.1K Q3 '24: 59.1K Q4 '24: 59.4K Q1 '25: 59.1K Q2 '25: 59.1K Q3 '25: 59.1K Q4 '25: 59.4K Q1 '26: 59.1K Q2 '26: 59.1K Q3 '26: 59.1K Q2 '14 Q1 '16 Q4 '17 Q3 '19 Q2 '21 Q1 '23 Q4 '24 Q3 '26

Gross Profit Quarterly

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Income Quarterly

-900K -600K -300K 0 300K 600K 900K Q2 '13: -70.5K Q3 '13: -74.8K Q1 '14: -185.8K Q2 '14: -170K Q3 '14: -157.9K Q4 '14: -192.6K Q1 '15: -213.4K Q2 '15: -621.4K Q3 '15: -621.4K Q4 '15: -523K Q1 '16: -689.5K Q2 '16: -719.9K Q3 '16: -870.8K Q4 '16: -676.9K Q1 '17: -533.6K Q2 '17: -659.2K Q3 '17: -553.1K Q4 '17: -780.1K Q1 '18: -879.6K Q2 '18: -447.7K Q3 '18: -125.2K Q4 '18: -263.3K Q1 '19: -198.8K Q2 '19: -230.8K Q3 '19: -137.7K Q4 '19: -189.4K Q1 '20: -134.7K Q2 '20: -39.3K Q3 '20: -16.3K Q4 '20: -18.9K Q1 '21: -18.5K Q2 '21: -13K Q3 '21: -42.5K Q4 '21: -126.8K Q1 '22: -106.4K Q2 '22: -76.5K Q3 '22: -58.9K Q4 '22: -97.8K Q1 '23: -463.9K Q2 '23: -78.8K Q3 '23: -85.2K Q4 '23: -59.1K Q1 '24: -122.8K Q2 '24: -101.1K Q3 '24: -108K Q4 '24: -85.4K Q1 '25: -61.4K Q2 '25: -113.3K Q3 '25: -40.8K Q4 '25: -123.1K Q1 '26: -551.6K Q2 '26: -153.7K Q3 '26: 24.5K Q2 '14 Q1 '16 Q4 '17 Q3 '19 Q2 '21 Q1 '23 Q4 '24 Q3 '26

Net Income Quarterly

-75M -50M -25M 0 25M 50M 75M Q1 '13: -91.8K Q2 '13: -70.5K Q3 '13: -74.8K Q4 '13: -117.9K Q1 '14: -209.5K Q2 '14: -186.2K Q3 '14: -166K Q4 '14: -194.6K Q1 '15: -219.2K Q2 '15: -8.8M Q3 '15: -1.6M Q4 '15: -600.7K Q1 '16: -1.9M Q2 '16: -1.1M Q3 '16: -2.4M Q4 '16: -2.4M Q1 '17: -2.5M Q2 '17: -1.3M Q3 '17: -2.6M Q4 '17: -1.3M Q1 '18: -2.8M Q2 '18: -1.1M Q3 '18: -107.6K Q4 '18: -981.6K Q1 '19: 245.1K Q2 '19: -333.2K Q3 '19: -4.4M Q4 '19: 1.9M Q1 '20: 3.1M Q2 '20: -4.1M Q3 '20: 3.2M Q4 '20: 1.2M Q1 '21: 1.7M Q2 '21: 442.2K Q3 '21: -7.5M Q4 '21: -1.4M Q1 '22: 2.6M Q2 '22: -67.1M Q3 '22: 67M Q4 '22: -78K Q1 '23: 1.6M Q2 '23: -55K Q3 '23: -99.2K Q4 '23: -325K Q1 '24: -144.9K Q2 '24: -122.5K Q3 '24: -130.1K Q4 '24: -264.9K Q1 '25: -515.4K Q2 '25: -19.4K Q3 '25: -167.3K Q4 '25: -572.5K Q1 '26: -967.9K Q2 '26: 991.9K Q3 '26: -637.8K Q2 '14 Q1 '16 Q4 '17 Q3 '19 Q2 '21 Q1 '23 Q4 '24 Q3 '26

Cost of Revenue Quarterly

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Cash Flow Quarterly

-1.2M -800K -400K 0 400K 800K 1.2M Q1 '15: -197.1K Q2 '15: -268.2K Q3 '15: -388.4K Q4 '15: -339K Q1 '16: -425.4K Q2 '16: -437.5K Q3 '16: -410.9K Q4 '16: -398.5K Q1 '17: -504.3K Q2 '17: -349.9K Q3 '17: -417.2K Q4 '17: -623K Q1 '18: -627.3K Q2 '18: -403.5K Q3 '18: -81.4K Q4 '18: -465.6K Q1 '19: -150K Q2 '19: -127.5K Q3 '19: -67.3K Q4 '19: -137K Q1 '20: 24.3K Q2 '20: -5.7K Q3 '20: 0 Q4 '20: 0 Q1 '21: 0 Q2 '21: 0 Q3 '21: -63.9K Q4 '21: -1.1M Q1 '22: -279.1K Q2 '22: -118.8K Q3 '22: -123.7K Q4 '22: -85.3K Q1 '23: -10.5K Q2 '23: -53K Q3 '23: -87K Q4 '23: -23.4K Q1 '24: -162.3K Q2 '24: -209.3K Q3 '24: -172.6K Q4 '24: -207.3K Q1 '25: -66.4K Q2 '25: -101.2K Q3 '25: -56K Q4 '25: -160K Q1 '26: -197.9K Q2 '26: -63.2K Q3 '26: -24.1K Q1 '16 Q3 '17 Q1 '19 Q3 '20 Q1 '22 Q3 '23 Q1 '25 Q3 '26

Free Cash Flow Quarterly

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Shares Outstanding Quarterly

0 2B 4B 6B Q2 '13: 10K Q3 '13: 24.2M Q1 '14: 51.8M Q2 '14: 51.9M Q3 '14: 51.9M Q1 '15: 52M Q2 '15: 72M Q3 '15: 110.6M Q1 '16: 118.2M Q2 '16: 124.9M Q3 '16: 128.8M Q1 '17: 143.6M Q2 '17: 141.8M Q3 '17: 138.1M Q1 '18: 143.1M Q2 '18: 145.3M Q3 '18: 153.5M Q1 '19: 211.9M Q2 '19: 295.7M Q3 '19: 85.9M Q1 '20: 836M Q2 '20: 1.6B Q3 '20: 1.6B Q1 '21: 1.8B Q2 '21: 2.5B Q3 '21: 3.6B Q1 '22: 4.5B Q2 '22: 3M Q3 '22: 3.2M Q1 '23: 3.4M Q2 '23: 1.7M Q3 '23: 3.4M Q1 '24: 3.6M Q2 '24: 4.1M Q3 '24: 4.2M Q1 '25: 4.1M Q2 '25: 21.6M Q3 '25: 23.8M Q1 '26: 99.6M Q2 '26: 184.9M Q3 '26: 615.6M Q3 '14 Q3 '16 Q3 '18 Q3 '20 Q3 '22 Q3 '24 Q3 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-0.27 -0.18 -0.09 0.00 0.09 0.18 0.27 Q4 '14: -0.01 Q1 '15: -0.01 Q2 '15: -0.13 Q3 '15: -0.14 Q4 '15: -0.13 Q1 '16: -0.14 Q2 '16: -0.02 Q3 '16: -0.03 Q4 '16: -0.06 Q1 '17: -0.06 Q2 '17: -0.06 Q3 '17: -0.06 Q4 '17: -0.12 Q1 '18: -0.12 Q2 '18: -0.12 Q3 '18: -0.10 Q4 '18: -0.03 Q1 '19: -0.01 Q2 '19: -0.00 Q3 '19: -0.06 Q4 '21: -0.00 Q1 '22: -0.00 Q4 '24: -0.16 Q1 '25: -0.25 Q2 '25: -0.22 Q3 '25: -0.20 Q1 '15 Q1 '16 Q1 '17 Q1 '18 Q1 '19 Q1 '22 Q3 '25

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.